Industry news

Russian pharmaceutical market grew by 7.84% in 2016

GMP News

In 2016, the volume of the Russian pharmaceutical market increased by 7.84% in end-consumer prices compared to 2015 and reached 1.21 trillion rubles, according to the information prepared by the Ministry of Industry and Trade for the meeting of its Board.

MIPT research may help look for new drugs

Marchmont Innovation News

Scientists at MIPT, one of Russia’s leading tech universities in Moscow, have developed a method of simulating cellular membrane response to drug and toxin molecules, a way of analyzing drugs’ impact on human cells prior to administering the drugs, and studying ageing mechanisms without any experiments. 

A pharmaceutical cluster is established in Moscow region

GMP News

The agreement was signed by IBPM of RAS, IPCP of RAS, ITEB of RAS, IFPB of RAS, BIBC of RAS, Hospital of ChSC of RAS, Hospital of PSC of RAS, Test Pushchino LLC, and Pre-Clinical Trials LLC. The agreement implies the integration of the competences of participants for development and trials of medicinal products.

Pharma's rep with patient groups was on the rise, but not anymore: PatientView

Beth Snyder Bulik / FiercePharmaMarketing

It may have been too good to last. After an upswing in pharma's global reputation in 2015, its standing among patient groups has swung the other way—again. Only 38% of patient groups said the industry had either an “excellent” or “good” reputation, down from almost 45% last year.

Three considerations for the pharma industry as President Trump focuses on drug pricing

By PwC Health Advisory: Karla Anderson, Rick Edmunds, Phil Sclafani, Doug Strang and Will Suvari / Endpoints News

As a presidential candidate, President Donald Trump repeatedly decried drug prices, suggesting that Americans should be allowed to purchase the products from abroad and that Medicare should be allowed to negotiate their prices. As president, he has continued to talk about drug pricing. Addressing Congress on Feb. 28, Trump said he would “work to bring down the artificially high cost of drugs, and bring them down immediately.”

23 March 2017

Neothetics Provides Business Update and Reports Fourth Quarter 2016 Financial Results

Neothetics, Inc. (NASDAQ:NEOT) today provided a business update and reported financial results for the fourth quarter 2016. “We are encouraged by our progress on our Phase 2 proof of concept trial for LIPO-202 in submental fat reduction and continue to expect top-line data in June 2017,” said Mr. Jeffrey M. Nugent, a member of Neothetics’ Operating Committee and Board of Directors.

New blood biomarker could enhance early detection of heart attack risk

Arlene Weintraub / FierceBiotech

When it comes to predicting who’s at risk of suffering a heart attack or other major cardiac events, physicians have long relied on detecting high levels of C-reactive protein (CRP), an inflammatory biomarker. But new research suggests CRP may not be the only game in town.

Big Pharma finds a hit with disease awareness social media posts in 2016

Beth Snyder Bulik / FiercePharmaMarketing

Pharma marketers continued to up their social media game in 2016, according to a new report, with many embracing disease awareness and charitable causes to drive engagement across social networks.

Doctors in New Zealand—the only non-U.S. country that allows DTC advertising—call for bans

Beth Snyder Bulik / FiercePharmaMarketing

Just like the United States does, New Zealand allows DTC pharma advertising. And just like in the U.S., many doctors there would like to ban the ads. Both the Royal New Zealand College of General Practitioners and the New Zealand Medical Association have come out recently with statements against DTC ads, as reported in New Zealand Doctor magazine. Both groups have called for a total ban on DTC ads, much the way the American Medical Association and American Society of Health-System Pharmacists did in the U.S.

What’s on biopharma’s auction block? EY tracks a growing appetite for pipeline divestment deals

John Carroll / Endpoints News

Last fall the research arm of the Financial Times went out and took the industry’s pulse on dealmaking. And they found that there’s been a big increase in appetite for divestments in the life sciences business, according to the EY M&A Outlook and Firepower Report 2017.